Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Evan Vellios

Sports Medicine Van Nuys, CA Medical Doctor

NPI 1609294479 CMS profile 8610365

6815 Noble Ave, Van Nuys, CA 91405

Open in the dashboard

General payments

$69,053

214 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evan Vellios of Van Nuys, CA is reported in the CMS Open Payments database as having received $69,053 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $33,774 60
2024 General $8,495 32
2023 General $11,450 58
2022 General $4,419 40
2021 General $1,647 13
2020 General $9,268 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evan Vellios
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Evan Vellios were reported at $33,774. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Evan Vellios Sports Medicine median Middle half National median
2019 $0 $1,176 $199–$4,249 $163
2020 $9,268 $708 $96–$2,890 $114
2021 $1,647 $1,213 $152–$3,994 $132
2022 $4,419 $1,230 $159–$3,998 $149
2023 $11,450 $584 $146–$2,836 $160
2024 $8,495 $628 $163–$3,168 $164
2025 $33,774 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Exactech, Inc. $45,063 40 payments
  2. Smith+Nephew, Inc. $9,299 44 payments
  3. Arthrex, Inc. $4,395 31 payments
  4. Saxum Surgical, Inc. $3,099 11 payments
  5. Synthes GmbH $2,260 4 payments
  6. Zimmer Biomet Holdings, Inc. $1,051 8 payments
  7. Micromed Inc $843 3 payments
  8. Stryker Corporation $806 12 payments
  9. Vericel Corporation $467 9 payments
  10. Osteoremedies, LLC $344 3 payments
  11. Other $1,428 49 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $36,632 14 payments
  2. Education $12,067 5 payments
  3. Food and Beverage $10,322 175 payments
  4. Travel and Lodging $8,532 19 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $1,500 1 payment
Products named General payments · program years 2020–2025
  1. EQUINOXE Orthopaedic $28,043 15 payments
  2. Equinoxe Orthopaedic $13,955 18 payments
  3. EQUINOXE PHX SYSTEM $1,906 4 payments
  4. EXACTECHGPS $1,027 2 payments
  5. Comp Reverse Shoulder Arcom $874 1 payment
  6. MACI $424 7 payments
  7. Remedy SPacer $214 2 payments
  8. Bone Anchors with Arthroscopic Delivery System $199 5 payments
  9. BioBrush $185 2 payments
  10. VARIAX $183 2 payments
  11. Other $5,514 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

495

Median for Orthopedic Surgery: 203

Drug cost

$3,193

Median for Orthopedic Surgery: $1,433

Branded share of claims

30.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 58 $1,170
Meloxicam Generic 114 $520
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 68 $414
Naproxen Generic 79 $289
Cyclobenzaprine Hcl Generic 42 $238
Ondansetron Odt Ondansetron Brand 58 $200
Ibuprofen Generic 18 $121
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 24 $106
Gabapentin Generic 16 $81
Tramadol Hcl Generic 18 $54

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$173,291

Of which drugs: $12,510

Medicare patients

376

Average age 74

Services billed

6,347

242 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 38%
Diabetes 34%
Osteoporosis 28%
Depression 26%
Chronic kidney disease 18%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 40 123 $11,694
Injection, methylprednisolone acetate, 1 mg J1010 Office 85 4,720 $478
Injection, methylprednisolone acetate, 40 mg J1030 Office 36 46 $232

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record